Previous 10 | Next 10 |
bluebird bio (NASDAQ: BLUE ): Q2 GAAP EPS of -$3.55 misses by $0.48 . More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Received EU conditional marketing authorization for ZYNTEGLO ® (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion dependent β-thalassemia (TDT) who do not have a β 0 /β 0 genotyp...
Quick Take Fulcrum Therapeutics ( FULC ) has filed to raise gross proceeds of $76.5 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing treatments for genetically-defined diseases with high unmet medical need and an initial focus on rare diseases...
bluebird bio ( BLUE ) was one of my best medium-term investments between February 2017 and March 2018. Since then, I have been patiently waiting to find a point to reenter the stock for a long-term investment as the company transitions into a commercial-stage company. The recent EU approval of...
Maxim upgrades Bluebird Bio (NASDAQ: BLUE ) from Hold to Buy with a $160 price target, a 30% upside. More news on: bluebird bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Array BioPharma is up 56% after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is higher by 8.35% after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...
Biotech targets that could see some interest today per Bloomberg after Pfizer ponied up a 62% premium for Array Bio Pharma include Biohaven (NYSE: BHVN ), Seattle Genetics (NASDAQ: SGEN ), Arena Pharmaceuticals (NASDAQ: ARNA ), Sage Therapeutics (NASDAQ: SAGE ), Sarepta Therapeutics (NASDAQ:...
Cowen analyst Yaron Werber says Bluebird (NASDAQ: BLUE ) reported "highly encouraging" Zynteglo data at the EHA meeting and announced higher-than-expected EU pricing. More news on: bluebird bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Bluebird (NASDAQ: BLUE ) comments on long-term safety and efficacy data for LentiGlobin gene therapy for Transfusion-dependent β-Thalassemia. More news on: bluebird bio, Inc., Healthcare stocks news, Read more ...
Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patient...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...